Geneva, Switzerland, and Paris, France, March 26, 2018 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) and Servier announced today positive results at 12 months from the CHANGE-MS Phase 2b study of GNbAC1, a novel and promising therapeutic approach for the treatment of multiple sclerosis (MS). The data showed that GNbAC1 administration had a significant, consistent positive impact on key neuroprotection markers known to be linked to disease progression. This is the first time that the benefit of a treatment targeting endogenous retrovirus protein is shown in a clinical trial.

For more information :